The Utility of Intramuscular Ziprasidone in the Management of Acute Pswychotic Agitation

References

• Asnis GM, Kaplan ML, Hundorfean G, Saeed W: Vio-lence and homicidal behaviors in psychiatric disorders. Psychiatr Clin North Am 1997; 20:405–424.
   PubMed Web of Science ®Google Scholar
• Currier GW, Trenton A: Pharmacological treatment of psychotic agitation. CNS Drugs 2000; 16:219–228.
   Google Scholar
• Zimbroff DL. Management of acute psychosis from emergency to stabilization. Available at: http://www.medscape.com/viewarticle/4601095. Accessed December 12, 2003.
   Google Scholar
• Schmidt AW, Lebel LA, Howard HR Jr, Zorn SH: Ziprasidone: A novel antipsychotic agent with a unique receptor binding profile. Eur J Pharmacol 2001; 425:197–201.
   PubMed Web of Science ®Google Scholar
• Gunasekara NS, Spencer CM, Keating GM: Ziprasi-done. A review of its use in schizophrenia and schizo-affective disorder. Drugs 2002; 62:1217–1251.
   Google Scholar
• Geodone [package insert]. New York, NY: Pfizer Inc; June 2002.
   Google Scholar
• Miceli JJ, Wilner KD, Tensfeldt TG: Pharmacokinetics of intramuscular ziprasidone in healthy volunteers: Results from two controlled studies [poster]. Presented at the 154th Annual Meeting of the American Psychiat-ric Association; May 5–10,2001; New Orleans, LA.
   Google Scholar
• Daniel DG, Potkin SG, Reeves KR, Swift RH, Harrigan EP: Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial. Psychopharmacol 2001; 155:128–134.
   PubMed Web of Science ®Google Scholar
• Lesem MD, Zajecka JM, Swift RH, Reeves KR, Harrigan EP: Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients. J Clin Psychiatry 2001; 62:12–18.
   PubMed Web of Science ®Google Scholar
• Swift RH, Harrigan EP, Cappelleri JC, Kramer D, Chandler LP: Validation of the behavioural activity rat-ing scale (BARS)TM: A novel measure of activity in agitated patients. J Psychiatr Res 2002; 36:87–95.
   PubMed Web of Science ®Google Scholar
• Brook S, Lucey JV, Gunn KP, for the Ziprasidone IM Study Group. Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psy-chosis. J Clin Psychiatry 2000; 61:933–941.
   Google Scholar
• Swift RH, Harrigan EP, van Kamen DP: A comparison of fixed-dose intramuscular (IM) ziprasidone with flexible-dose IM haloperidol [poster]. Presented at the 151st Annual Meeting of the American Psychiatric Association; May 30-June 4, 1998; Toronto, Ontario, Canada.
   Google Scholar
• Brook S, Walden J, Benettia I: Ziprasidone versus haloperidol in sequential IM/oral treatment of acute schizophrenia [poster]. Presented at the 40th Annual Meeting of the American College of Neuropsychophar-macology; December 9–13,2001; Waikoloa, Hawaii.
   Google Scholar
• Pfizer Inc. FDA Psychopharmacological Drugs Advi-sory Committee: Briefing document for ziprasidone mesy-late for intramuscular injection: 15 February 2001. New York, NY: Pfizer Inc.
   Google Scholar
• Zimbroff DL, Brook S, Benattia I: Safety and tolerabil-ity of IM ziprasidone: Review of clinical trial data [poster]. Presented at the 155th Annual Meeting of the American Psychiatric Association; May 18–23, 2002; Phila-delphia, PA.
   Google Scholar
• Daniel D, Brook S, Benattia I: Transition from IM to oral ziprasidone: Clinical efficacy and safety data [poster]. Presented at the 155th Annual Meeting of the American Psychiatric Association; May 18–23, 2002; Philadelphia, PA.
   Google Scholar
• Miceli JJ, Anziano RJ, Swift RH, Tensfeldt TG, Shiovitz T: IM ziprasidone and IM haloperidol have comparable effects on QT, at Cm. Presented at the 155th Annual Meeting of the American Psychiatric Association; May 18–23,2002, Philadelphia, PA.
   Google Scholar
• Allen MH, Zimbroff DL, Jagoda AS: Treatment of acute agitation with atypical antipsyhotics 2003; 20. Available at: http://www.physweekly.com/specialissue XX24.asp?issueid 73. Accessed December 13,2003.
   Google Scholar
• Clinton JE, Sterner S, Stelmachers Z, Ruiz E: Haloperi-dol for sedation of disruptive emergency patients. Ann Emerg Med 1987; 16:319–322.
   Google Scholar
• Citrome L: Current treatments of agitation and aggres-sion. Available at: htqxhivww.medscape.com/Yiewprogram/ 1866. Accessed December 12,2003.
   Google Scholar
• Citrome L: Atypical antipsychotics for acute agitation. New intramuscular options offer advantages. Postgrad Med 2002; 112:85-88,94–6.
   Google Scholar
• Salzman C, Solomon D, Miyawaki E, et al. Parenteral lorazepam versus parenteral haloperidol for the control of psychotic disruptive behavior. J Clin Psychiatry 1991; 52:177–180.
   PubMed Web of Science ®Google Scholar
• Foster S, Kessel J, Berman ME, Simpson GM: Efficacy of lorazepam and haloperidol for rapid tranquilization in a psychiatric emergency room setting. Int Clin Psy-chopharmacol 1997; 12:175–179.
   PubMed Web of Science ®Google Scholar
• Hughes DH: Acute psychopharmacological manage-ment of the aggressive psychotic patient. Psychiatr Serv 1999; 50:1135–1137.
   PubMedGoogle Scholar
• Battaglia J, Moss S, Rush J, et al. Haloperidol, lorazepam, or both for psychotic agitation? A multi-center, prospective, double-blind, emergency depart-ment study. Am J Emerg Med 1997; 15:335–340.
   PubMed Web of Science ®Google Scholar
• Bieniek SA, Ownby RL, Penalver A, Dominguez RA: A double-blind study of lorazepam versus the combina-tion of haloperidol and lorazepam in managing agita-tion. Pharmacotherapy 1998; 18:57–62.
   PubMed Web of Science ®Google Scholar
• FDA Psychopharmacological Drugs Advisory Com-mittee. Briefing document for ZYPREXA IntraMuscu-lar (olanzapine for injection). February 14, 2001. Available at: http://www.fda.gov/ohrms/dockets/ac/01/ briefing/3685b1 01 lilly.pdf Accessed December 15, 2003.
   Google Scholar
• Wright P, Birkett M, David SR, et al. Double-blind, placebo-controlled comparison of intramuscular olan-zapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am J Psychiatry 2001; 158:1149–1151.
   PubMed Web of Science ®Google Scholar
• Altamura AC, Sassella F, Santini A, Montresor C, Fumagalli S, Mundo E: Intramuscular preparations of antipsychotics: Uses and relevance in clinical practice. Drugs 2003; 63:493–512.
   PubMed Web of Science ®Google Scholar
• Meehan K, Zhang F, David S, et al. A double-blind, ran-domized comparison of the efficacy and safety of intra-muscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipo-lar mania. J Clin Psychopharmacol 2001; 21:389–397.
   PubMed Web of Science ®Google Scholar
• Wright P, Jewell H, Michell M, et al. A preliminary study of the safety, efficacy and pharmacokinetics of intramuscular olanzapine in patients with acute nonor-ganic psychosis [abstract]. Schizophren Res 1999; 36:318.
   Google Scholar
• Wright P, Kiesler G, Michell M, et al. Safety and effi-cacy of intramuscular olanzapine in patients with acute nonorganic psychosis [abstract]. Schizophren Res. 1999; 36:318.
   Google Scholar
• Currier GW, Simpson GM: Risperidone liquid concentrate and oral lorazepam versus intramuscular haloperidol and intramuscular lorazepam for treatment of psychotic agitation. J Clin Psychiatry 2001; 62:153–157.
   PubMed Web of Science ®Google Scholar
• Russell TM, Mackell JA, Leaderer MC. Economic model of IM ziprasidone and IM haloperidol in acute agitation [poster]. Presented at the American Psychiat-ric Association 55th Institute on Psychiatric Services; October 29—November 2, 2003; Boston, MA.
   Google Scholar
• Pondrom M, Ducate SE. Ziprasidone reduces phar-macy costs for correctional inpatients [poster]. Pre-sented at the American Psychiatric Association 55th Institute on Psychiatric Services; October 29—November 2, 2003; Boston, MA.
   Google Scholar